ContraFect Corp
Company Profile
Business description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Contact
28 Wells Avenue
3rd Floor
YonkersNY10701
USAT: +1 914 207-2300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
23
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.60 | 95.80 | -1.07% |
| CAC 40 | 8,080.74 | 66.09 | -0.81% |
| DAX 40 | 25,463.81 | 272.43 | -1.06% |
| Dow JONES (US) | 49,165.59 | 1,032.58 | -2.06% |
| FTSE 100 | 10,452.68 | 98.49 | -0.93% |
| HKSE | 22,841.62 | 453.13 | -1.95% |
| NASDAQ | 23,911.90 | 517.98 | -2.12% |
| Nikkei 225 | 59,444.21 | 419.93 | 0.71% |
| NZX 50 Index | 14,247.25 | 17.04 | -0.12% |
| S&P 500 | 7,185.87 | 137.76 | -1.88% |
| S&P/ASX 200 | 8,730.40 | 91.40 | -1.04% |
| SSE Composite Index | 3,577.62 | 10.21 | -0.28% |